NCI Funds 4-Year Projects at 12 Tobacco Research Centers

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 12
Volume 9
Issue 12

BETHESDA, Md-The National Cancer Institute (NCI) has launched its new antismoking initiative, Research in State and Community Tobacco Control Interventions, by awarding 12 grants totaling $13 million. The money will support the first year of 4-year research projects on local, state, and multistate tobacco prevention and control programs.

BETHESDA, Md—The National Cancer Institute (NCI) has launched its new antismoking initiative, Research in State and Community Tobacco Control Interventions, by awarding 12 grants totaling $13 million. The money will support the first year of 4-year research projects on local, state, and multistate tobacco prevention and control programs.

The first awards in the NCI program went to researchers at the University of Alabama at Birmingham; AMC Cancer Research Center, Denver; University of Illinois at Chicago; Battelle Centers for Public Health Research and Evaluation, Baltimore; and University of Massachusetts campuses at Amherst and Boston.

Grants also went to the University of Massachusetts Medical School; University of Minnesota School of Public Health; Roswell Park Cancer Institute; Oregon Research Institute, Eugene; Kaiser Permanente Center for Health Research, Portland, Oregon; and University of Texas Health Science Center at Houston.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
4 experts in this video
2 experts are featured in this series.
4 experts in this video
5 experts are featured in this series
5 experts are featured in this series
Osimertinib/chemotherapy and amivantamab/lazertinib have exhibited an efficacy advantage vs osimertinib in patients with EGFR-mutant NSCLC.
Related Content